Matrix metalloproteinases in peripheral blood and cerebrospinal fluid in patients with Alzheimer's disease
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Deposition of amyloid beta in senile plaques and in cerebral blood vessels is one hallmark of the pathogenesis of Alzheimer's disease (AD). The ability of several matrix metalloproteinases (MMPs) to degrade amyloid precursor protein leading to aggregation of amyloid beta, as well as the increased expression of MMPs in post mortem brain tissue of Alzheimer's patients, indicate that MMPs play an important role in the pathogenesis of AD. METHODS: We investigated levels of MMP-2,-3,-9 and -10 in plasma and cerebrospinal fluid (CSF) of AD patients (n = 14) by gelatin and casein zymography. Comparisons between AD patients and controls relative to levels of MMP-2, MMP-3, MMP-9, and MMP-10 were made with Wilcoxon rank statistics. Pearson correlations were computed as measures of association. RESULTS: MMP-3 in AD was significantly elevated in plasma (p = 0.006) and there was a trend towards increase in CSF (p = 0.05). MMP-2 in CSF of AD patients was significantly decreased (p = 0.02) while levels in plasma remained unchanged. MMP-9 and MMP-10 could not be detected in CSF; MMP-10 was unchanged in plasma, but MMP-9 was significantly decreased (p = 0.02). CONCLUSIONS: These findings constitute further evidence for the important role of MMPs in the pathogenesis of AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Backstrom, J. R., Lim, G. P., Cullen, M. J., & Tökés, Z. A. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-24-07910.1996 · Cited by 331 · cited 3×
“Backstrom et al. argued that the inflammatory protein α1antichymotrypsin, which accumulates in amyloid plaques and which is a known inhibitor of serine proteinases, may prevent activation of MMP-9 and thereby contribute to reduced cleavage of amyloid β (Backstrom et al., 1996).”
BackgroundInfluentialWhite, A. R., Du, T., Laughton, K. M., Volitakis, I., Sharples, R. A., Xilinas, M. E., Hoke, D. E., Holsinger, R. M. D., Evin, G., Cherny, R. A., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m602487200 · Cited by 284
Selective distribution of matrix metalloproteinase-3 (MMP-3) in Alzheimer’s disease brain
Yoshiyama, Y., Asahina, M., & Hattori, T. (2000) · Acta Neuropathologica · doi:10.1007/pl00007428 · Cited by 128 · cited 4×
“It plays an important role in activating MMP-9, which is involved in amyloid β degradation (Yoshiyama et al., 2000) as well as being directly involved in amyloid β degradation itself (White et al., 2006).”
BackgroundResultInfluential
Research works printed but not linked: 27
- Adair, 2004, Measurement of gelatinase B (MMP-9) in the cerebrospinal fluid of patients with vascular dementia and Alzheimer disease, Stroke, 35, e159, 10.1161/01.STR.0000127420.10990.76 · DOI · Paper page
- Alvarez-Sabin, 2004, Temporal profile of matrix metalloproteinases and their inhibitors after spontaneous intracerebral hemorrhage: relationship to clinical and radiological outcome, Stroke, 35, 1316, 10.1161/01.STR.0000126827.69286.90 · DOI · Paper page
- Bar-Or, 2003, Analyses of all matrix metalloproteinase members in leukocytes emphasize monocytes as major inflammatory mediators in multiple sclerosis, Brain, 126, 2738, 10.1093/brain/awg285 · DOI · Paper page
- Beuche, 2000, Matrix metalloproteinase-9 is elevated in serum of patients with amyotrophic lateral sclerosis, Neuroreport, 11, 3419, 10.1097/00001756-200011090-00003 · DOI · Paper page
- Beyzade, 2003, Influences of matrix metalloproteinase-3 gene variation on extent of coronary atherosclerosis and risk of myocardial infarction, Journal of the American College of Cardiology, 41, 2130, 10.1016/S0735-1097(03)00482-0 · DOI
- Campbell, 1999, Matrix metalloproteinases and their inhibitors in the nervous system: the good, the bad and the enigmatic, Trends in Neurosciences, 22, 285, 10.1016/S0166-2236(99)01430-7 · DOI
- Deb, 2003, Beta-amyloid induces the production of active, matrix-degrading proteases in cultured rat astrocytes, Brain Research, 970, 205, 10.1016/S0006-8993(03)02344-8 · DOI · Paper page
- Flex, 2006, Analysis of functional polymorphisms of metalloproteinase genes in persons with vascular dementia and Alzheimer's disease, Journals of Gerontology, Series A: Biological Sciences and Medical Sciences, 61, 1065, 10.1093/gerona/61.10.1065 · DOI · Paper page
- Helbecque, 2003, The role of matrix metalloproteinase-9 in dementia, Neuroscience Letters, 350, 181, 10.1016/S0304-3940(03)00905-4 · DOI
- Helbecque, 2007, Impact of the matrix metalloproteinase MMP-3 on dementia, Neurobiology of Aging, 28, 1215, 10.1016/j.neurobiolaging.2006.05.030 · DOI
- Hofman, 1997, Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study, Lancet, 349, 151, 10.1016/S0140-6736(96)09328-2 · DOI · Paper page
- Horstmann, 2003, Profiles of matrix metalloproteinases, their inhibitors, and laminin in stroke patients: influence of different therapies, Stroke, 34, 2165, 10.1161/01.STR.0000088062.86084.F2 · DOI · Paper page
- Lorenzl, 2003, Tissue inhibitors of matrix metalloproteinases are elevated in cerebrospinal fluid of neurodegenerative diseases, Journal of the Neurological Science, 207, 71, 10.1016/S0022-510X(02)00398-2 · DOI · Paper page
- Lorenzl, 2003, Increased plasma levels of matrix metalloproteinase-9 in patients with Alzheimer's disease, Neurochemistry International, 43, 191, 10.1016/S0197-0186(03)00004-4 · DOI · Paper page
- Lorenzl, 2008, Profiles of matrix metalloproteinases and their inhibitors in plasma of patients with dementia, International Psychogeriatrics, 20, 67, 10.1017/S1041610207005790 · DOI · Paper page
- Martin-Aragon, 2009, Metalloproteinase's activity and oxidative stress in mild cognitive impairment and Alzheimer's disease, Neurochemical Research, 34, 373, 10.1007/s11064-008-9789-3 · DOI
- McGeer, 1998, The importance of inflammatory mechanisms in Alzheimer disease, Experimental Gerontology, 33, 371, 10.1016/S0531-5565(98)00013-8 · DOI · Paper page
- Montaner, 2001, Matrix metalloproteinase expression after human cardioembolic stroke: temporal profile and relation to neurological impairment, Stroke, 32, 1759, 10.1161/01.STR.32.8.1759 · DOI · Paper page
- Mrak, 2007, Common inflammatory mechanisms in Lewy body disease and Alzheimer disease, Journal of Neuropathology and Experimental Neurology, 66, 683, 10.1097/nen.0b013e31812503e1 · DOI · Paper page
- Pollanen, 2002, Coronary artery calcification is related to functional polymorphism of matrix metalloproteinase 3: the Helsinki Sudden Death Study, Atherosclerosis, 164, 329, 10.1016/S0021-9150(02)00107-7 · DOI
- Pollanen, 2005, Matrix metalloproteinase3 and 9 gene promoter polymorphisms: joint action of two loci as a risk factor for coronary artery complicated plaques, Atherosclerosis, 180, 73, 10.1016/j.atherosclerosis.2004.10.041 · DOI
- Pozzi, 2000, Elevated matrix metalloprotease and angiostatin levels in integrin alpha 1 knockout mice cause reduced tumor vascularization, Proceedings of the National Academies of Sciences, 97, 2202, 10.1073/pnas.040378497 · DOI · Paper page
- Reitz, 2008, Matrix metalloproteinase 3 haplotypes and dementia and Alzheimer's disease: the Rotterdam Study, Neurobiology of Aging, 29, 874, 10.1016/j.neurobiolaging.2007.01.001 · DOI
- Roher, 1994, Proteolysis of A beta peptide from Alzheimer disease brain by gelatinase A, Biochemical and Biophysical Research Communication, 205, 1755, 10.1006/bbrc.1994.2872 · DOI · Paper page
- Saarela, 2004, Interaction between matrix metalloproteinase 3 and the epsilon4 allele of apolipoprotein E increases the risk of Alzheimer's disease in Finns, Neuroscience Letters, 367, 336, 10.1016/j.neulet.2004.06.027 · DOI
- Thorns, 2003, Expression of MMP-2, MMP-7, MMP-9, MMP-10 and MMP-11 in human astrocytic and oligodendroglial gliomas, Anticancer Research, 23, 3937
- Woessner, 1991, Matrix metalloproteinases and their inhibitors in connective tissue remodeling, FASEB Journal, 5, 2145, 10.1096/fasebj.5.8.1850705 · DOI · Paper page
Cited by
Matrix metalloproteinases in the brain and blood–brain barrier: Versatile breakers and makers
Rempe, R. G., Hartz, A. M., & Bauer, B. (2016) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x16655551 · Cited by 721
Ageing, Cellular Senescence and Neurodegenerative Disease
Kritsilis, M., V. Rizou, S., Koutsoudaki, P. N., Evangelou, K., Gorgoulis, V. G., & Papadopoulos, D. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19102937 · Cited by 448
Amyloid-Beta Protein Clearance and Degradation (ABCD) Pathways and their Role in Alzheimer’s Disease
Baranello, R., Bharani, K., Padmaraju, V., Chopra, N., Lahiri, D., Greig, N., Pappolla, M., & Sambamurti, K. (2015) · Current Alzheimer Research · doi:10.2174/1567205012666141218140953 · Cited by 331
“Brain imaging studies utilizing the Pittsburgh compound B show that in comparison to ApoE4-ε4-negative subjects, cognitively normal middle-aged subjects carrying the ApoE-ε4 allele have a far greater likelihood of having a higher cerebral amyloid load [43, 53] and, consequently, lower levels of cerebrospinal fluid (CS…”
ResultInfluentialCellular Senescence in Neurodegenerative Diseases
Martínez-Cué, C., & Rueda, N. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00016 · Cited by 281
Oxidative stress and β-amyloid protein in Alzheimer’s disease
Cai, Z., Zhao, B., & Ratka, A. (2011) · NeuroMolecular Medicine · doi:10.1007/s12017-011-8155-9 · Cited by 279
“MMPs are involved in various steps of pathogenesis of AD, including focal BBB damage (Leake et al. 2000), formation of amyloid plaques (Horstmann et al. 2010; Liao and Van Nostrand 2010), tau hyper-phosphorylation (Lee et al. 2009), perivascular lymphocyte infiltration, and loss of axons.”
Background
Metadata
- Authors
- Horstmann, S., Budig, L., Gardner, H., Koziol, J., Deuschle, M., Schilling, C., & Wagner, S.
- Venue
- International Psychogeriatrics
- Publisher
- Elsevier BV
- Published
- 2010-09
- Volume
- 22
- Issue
- 6
- Pages
- 966-972
- ISSN
- 1041-6102 (ISSN-L)
- OpenAlex
- W2129034908
- Cited by
- 110
- References
- 3
- FWCI
- 3.42
- Type
- journal article
- Language
- en
- Open access
- gold
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor, 5235 d)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Matrix metalloproteinases in peripheral blood and cerebrospinal fluid in patients with Alzheimer's disease. https://app.cochat.ai/papers/10.1017/s1041610210000827
- The paper
- Horstmann, S., Budig, L., Gardner, H., Koziol, J., Deuschle, M., Schilling, C., & Wagner, S. (2010). Matrix metalloproteinases in peripheral blood and cerebrospinal fluid in patients with Alzheimer's disease. International Psychogeriatrics. https://doi.org/10.1017/s1041610210000827
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.